<SEC-DOCUMENT>0001213900-23-091702.txt : 20231201
<SEC-HEADER>0001213900-23-091702.hdr.sgml : 20231201
<ACCEPTANCE-DATETIME>20231201073526
ACCESSION NUMBER:		0001213900-23-091702
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231201
FILED AS OF DATE:		20231201
DATE AS OF CHANGE:		20231201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		231457546

	BUSINESS ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea189322-6k_nlspharma.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of December 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-39957</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>NLS
PHARMACEUTICS LTD.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Circle 6</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>8058
Zurich, Switzerland</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2023, NLS Pharmaceutics Ltd., or the Registrant, issued a press release titled: &ldquo;NLS Pharmaceutics Announces Exclusive
Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.&rdquo; A copy of this
press release is furnished herewith as Exhibit 99.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Registrant&rsquo;s Registration Statements on Form
F-3&nbsp;<FONT STYLE="background-color: white">(File Nos.&nbsp;</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390022005236/ea154797-f3_nlspharma.htm"><FONT STYLE="background-color: white">333-262489</FONT></A><FONT STYLE="background-color: white">,
</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390022077965/ea169650-f3_nlspharm.htm"><FONT STYLE="background-color: white">333-268690</FONT></A><FONT STYLE="background-color: white">&nbsp;and&nbsp;</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1783036/000121390023002775/ea171509-f3_nlspharm.htm"><FONT STYLE="background-color: white">333-269220</FONT></A><FONT STYLE="background-color: white">),</FONT>&nbsp;filed
with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not
superseded by documents or reports subsequently filed or furnished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of Document</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="ea189322ex99-1_nlspharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release titled: &ldquo;NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS
    Pharmaceutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    December 1, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander
    Zwyer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea189322ex99-1_nlspharma.htm
<DESCRIPTION>PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES EXCLUSIVE OPTION AGREEMENT TO DEVELOP AND COMMERCIALIZE NEXT GENERATION DUAL OREXIN AGONIST PLATFORM OF AEXON LABS, INC."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NLS Pharmaceutics Announces Exclusive Option
Agreement to Develop and<BR>
 Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><I>The option agreement grants NLS Pharmaceutics Ltd. the
exclusive option to in-license all of Aexon Labs&rsquo; assets for the potential treatment of narcolepsy and other neuro-degenerative
disorders, and all future indications</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.15pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><I>Exclusive option agreement accesses global rights to multiple
highly selective Orexin-1 / Orexin-2 receptor agonists, unique compounds designed for specificity, acting multiple pathways involved
in the pathophysiology of narcolepsy and other central disorders of hypersomnolence</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.15pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><I>Additional targets include Cathepsin-H inhibition, sigma-1
receptor agonist, DAT and NET reuptake inhibition, addressing neurotransmission, neuroprotection and neuroinflammation</I></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>First
patent application filed at the end of 2022 for orexin receptors agonists for treating or preventing neurological diseases and psychiatric
disorders including narcolepsy</I></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>NLS
continues to strengthen its neuroscience pipeline in sleep medicine with a unique and holistic approach to central disorders of hypersomnolence
and neurodegenerative disorders franchise</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Z&uuml;rich, Switzerland,
December 1, 2023</B> &ndash; NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (&ldquo;NLS&rdquo; or the &ldquo;Company&rdquo;), a Swiss clinical-stage
biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central
nervous system (&ldquo;CNS&rdquo;) disorders, today announced that NLS has entered into an exclusive worldwide option agreement with Aexon
Labs, Inc., a privately held U.S. company (&ldquo;Aexon Labs&rdquo;), under which NLS may acquire global development and commercialization
rights to Aexon Labs&rsquo; Dual Orexin Receptor Agonists platform, new molecular entities, highly selective dual oral orexin-1 and orexin-2
receptor agonists (OX1R and OX2R) with potential applications in the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative
disorders such as Parkinson&rsquo;s and Alzheimer&rsquo;s disease. This option agreement represents a potentially leading next-generation,
first-in-class, oral, dual orexin receptor agonist (AEX-2) that is expected to address high unmet medical needs and has shown promising
results in pre-clinical in vitro assays. Aexon Labs has plans to initiate clinical development, including Phase 1 First-in-Human and Phase
1b Proof-of-Concept (POC) studies, as early as 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The transaction will
be structured as an exclusive worldwide license for the development and commercialization by NLS of the Aexon Labs&rsquo; compounds and
their derivatives. Under the terms of the option agreement, NLS must exercise its option by no later than March 31, 2024. NLS will pay
Aexon Labs an upfront payment of $30,000 for the option exclusivity, and $170,000 upon execution of the definitive agreement to exercise
the option. In addition, Aexon Labs will receive 15% of all proceeds earned by NLS in any future sub-licensing agreements which include
upfront payments, regulatory milestones, commercial milestones and royalties earned during the first three years of commercialization
in the U.S. and in the EU. Royalties will be payable, on a country-by-country basis, from the date of first commercial sale of a product
in a given country until the date of patent expiry or the entry of a generic version of the product in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">NLS will be the sole
party responsible for the design and execution of the research and development plan, for the conduct and management of the preclinical
as well as clinical studies, and for the interactions with the U.S. Food and Drug Administration and/or any other regulatory agency. NLS
will pay all costs associated with executing and completing those studies, as well as those associated with the preparation and submission
of a new drug application. NLS will pay for all studies in all indications and regulatory filings in the U.S. as well as outside of the
U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Eric Konofal, MD, PhD,
who works under a part-time consulting agreement for NLS as its Chief Scientific Officer, is the president and founder of Aexon Labs,
and owns 59% of Aexon Labs. Alexander Zwyer, Chief Executive Officer of NLS, owns 35% of Aexon Labs. Mr. Zwyer holds no board or executive
position at Aexon Labs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mr. Zwyer said,
&ldquo;I believe the potential acquisition of this novel and unique platform, which consists of over 300 compounds, bridges the
present to the future treatment of sleep disorders as well as other neuro-degenerative disorders. These new compounds, in addition
to our current pipeline, including Mazindol ER for the treatment of narcolepsy, along with NLS-4 focused on idiopathic hypersomnia,
long-COVID and chronic fatigue syndrome, and NLS-11, addressing Kleine-Levin Syndrome and neurodegenerative diseases, will further
complement and strengthen our hypersomnia franchise.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Orexin receptor pathways
play vital regulatory roles in many physiological processes and studies have shown that orexin receptor pathways are involved in pathological
processes of neurological diseases such as narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About Narcolepsy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Narcolepsy is a
life-long sleep disorder caused by the autoimmune-mediated loss of 70,000&ndash;90,000 orexin-producing neurons in the hypothalamus,
characterized by excessive daytime sleepiness, cataplexy and rapid eye movement sleep abnormalities, and is tightly associated with
human leukocyte antigen&nbsp;HLA-DQB1*06:02. Other predisposing factors for narcolepsy are associations with a polymorphism in
the&nbsp;T-cell receptor alpha and beta genes, whose products recognize antigens presented by human leukocyte
antigens (HLA) molecules, and&nbsp;Cathepsin H (CTSH).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About NLS Pharmaceutics
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">NLS is a global development-stage
biopharmaceutical company,&nbsp;working with a network of world-class partners and internationally recognized scientists, focused on the
discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical
needs. Headquartered in Switzerland and founded in 2015, NLS is&nbsp;led by an experienced management team with a track record of developing
and commercializing product candidates.&nbsp; For more information, please visit&nbsp;www.nlspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About Aexon Labs,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Aexon Labs is conducting
leading edge research on new compounds to address unmet needs in neurodegenerative disorders, defined by the breakdown of neurons over
time. Alzheimer&rsquo;s, Parkinson&rsquo;s, Huntington&rsquo;s, Narcolepsy and Amyotrophic Lateral Sclerosis are just a few examples of
brain disorders that have no cure. Current treatments do not address the root cause of each disorder and often lack therapeutical effectiveness
and safety for these neurological disorders. For more information, please visit&nbsp;www.aexonlabs.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release contains
expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements
when it discusses the potential benefits of NLS&rsquo; and Aexon Labs&rsquo; products, development plans and timing of studies, and the
timing and the expected outcome of the option agreement. These forward-looking statements and their implications are based on the current
expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results
to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter
delays or obstacles in launching and/or successfully completing its clinical trials; NLS&rsquo; products may not be approved by regulatory
agencies, NLS&rsquo; technology may not be validated as it progresses further and its methods may not be accepted by the scientific community;
NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific
difficulties may develop with NLS&rsquo; process; NLS&rsquo; products may wind up being more expensive than it anticipates; results in
the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with
the results of human clinical trials; NLS&rsquo; patents may not be sufficient; NLS&rsquo; products may harm recipients; changes in legislation
may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss of market share
and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from
those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release
any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading &ldquo;Risk
Factors&rdquo; in NLS&rsquo; annual report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission
(SEC), which is available on the SEC&rsquo;s website, www.sec.gov, and in subsequent filings made by NLS with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For additional information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marianne Lambertson (investors &amp; media)<BR>
NLS Pharmaceutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 239.682.8500<BR>
ml@nls-pharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.nlspharmaceutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F 5D# 2(  A$! Q$!_\0
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M,ZDU)704444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8 HKSO2I=>\=/>7\6MRZ5I\4[0P0VR@N=O=C78:%I^H:=9O#J.J/J#[R4E=
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M(T#D>8JC!!]QVI]_?W]I,GDZ:]U"5^9HW (;TQ5+0M/NH]1OM1N(%MA<X"P
MYP!W/O04E:M[JO??3;3H_P!#?HHHI'85=2MYKO3;BWMYC#-)&520?PFL?1O#
MLL/AZ73-7F%TLK$XR3M'8 GGKS7145:FTK(#C]2M[3P+X=N[W3(2UPY5 \IW
M8)/&?85Q^A^,-3OM6BT_59%O;*]<0R1.@XW<9&*]7O["VU.QEL[N,20RC#+7
M&S^'-"\#6L_B"07%RUMS$CL.&)P,>_/4UM"I%I\VK8',>)?A5?P3O<:(PN8#
MSY#MAU]@>AKCW\)^(8Y/+;1;W=GM$2/S'%>Q>#?'D7BN2Y@:S:VN(%\S:&W!
MESCCWKS+4_B%XCGUF:>"_>WC20A($ V  XP1WJX.HW9B+.B?##7=0N%DO8Q8
M0#JTA!?'LH_K6OXJU:;P2\'A_P /G[*BQB6:<J&>5C[GZ5U%]X^32_!6G:U<
M6IDN;Q0$A4X!;')SV'&:HV<6C?%33/MEQ;S6=[:-Y3&-@2,\]>XJ.9WO-:":
M[$7A*^_X3_1;S3-?3SGMF5TG3Y6YSCIW&#^==+_PBD.G^%[S2M%D:UEG4_OV
M8EBWN?IQ5SP_X<L/#5DUM8HWSG=)(YRSGWK7K*4]?=V!1[F'X3TF^T70H[/4
M+O[3,'9MV20H/1036Y114-W=QI6T"BBBD,**** "BBB@"I?ZE;Z<B&8NSR-M
MCBC7<[GT I;.\-XKDVUQ 5.,3)M)^G)K*U25+#Q'97]T"+3R'A\W&1$Y(()]
M,@8S3]9U%+G0+R33+D2E-H=K<[F521NQCOC-7;8RY[-WZ=#<SFBN5L_L::Y&
MFC2%[9K5S<A'+)GC83G^+K5+3[80:;X?U!&F^US7"QRR%V)9#NRI'ITHY1>U
M\OZT_P SMZ.E<A>64=W=>))9C*6MU5H,.P\MO+SD8[Y HU2>>:+1#<O$+66#
M=*TY81M)M& V/QQGBCE#VMNG]7L=?3))8X87ED8+&BEF8]@.M<K.)K7PS"IO
M!-:&[ FEMV8[("W(!ZX'3/I5^6UTN7PWJ$6G".2$QN2(G+#=MX[_ $HY1^T;
M-66]BCL?MBAY8MH8>4I8L#TP/QJQGC-<G,;>/X>.U@_'DH6,;$D/E<_0U=U2
MV2]U_2[>;>T#0RET#$!L;<9Q1RASO\OQ.@HSFN/+7,/A6]AA>;RX+UHB5)+K
M '&<'KP,U/I)T]?%/EZ7(6MOL1)57)3=O'3/?'6CE$JNJ1O:AJ$6FVZS3+(P
M9UC58URQ8G %-L=3@OWFC198IH2!)%*NUEST/T-9WBP@:9;%I3$HO(29!_ -
MW6J>EO\ Z3K8BN#>QF(-]L(Y+;3\F1P<>WK0HKEN#FU.QU5,DD$<3R8+!5+8
M49)QZ5RML8=-\$173PO.]S''YQDD;DM@98]E&>W:FZ.[)!K\,<L;0H@:/R"V
MQ24.=N3ZBCE#VNR[G5P2B>".9590ZA@'&",^H[5)7*2QFYTSPS%(TNV1D$F&
M(+#RSD$U+90K!#KU@ER]K;1OB)RQ/DAD!.">V:.4:J/M_5KG39S16!X6EC,%
MU;)%$# ZJTT#EHY21U!/?UK?J6K.Q<9<RN%%%%(H**** "BBB@ HHHH *YGQ
M?K?AZRMDTK7F8QWPV[%4G R/F)'3!QS735EZKX=TG6Y;>34;*.=[<YC+9&/;
MCJ/8U4;)Z@5/#?A+2?#2ROIR.7G W2R/N)7L![50O_AMX=U#5&OY()49VWR1
MQR;4<_3M^%=<!@8'2BCGE>]P,?6/#&EZYI":9=V^+>+'E",[3'@8&/PK%\+W
MOA?1=4F\*Z2\@NT8M(7!/F.!S\W<@5V59</AS2+?6Y=8BLHUOY1AIAG)SU..
M@/O0I:68&I1114@%%%% !1110 4444 %%%% "$!@0P!!Z@TB1I$NV-%0>BC%
M.HH :D<<8(1%4$Y(48S2[%P!M&!T&.E+10 FU>?E'/7CK2-&CIL9%9?[I&13
MJ* &A%5-BJ O3 '%"1I$NV-%0>BC%.HH :(HU0HJ*%/) '%+@9!P,CH:6B@"
M*>)I('CBD,+L.)$ R#Z\\53L=*^RW<EW-<O<7#H(PS*%"KG. !QUK1HIW$XI
MNXUT61=KJ&7T(S2JBJNU5 7T XI:*0Q"BE-A4;<8QCBD6-%&%10,8P!VIU%
M";5X^4<=..E&Q3GY1\W7CK2T4 -1$C4*BJJCLHP*=110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
